Literature DB >> 28741476

Squamous Transition of Lung Adenocarcinoma and Drug Resistance.

Shenda Hou1, Xiangkun Han1, Hongbin Ji2.   

Abstract

Studies in mouse models support an essential role of lung adenocarcinoma (ADC) to squamous cell carcinoma (SCC) transition (AST) in the development of drug resistance. Recent observations in the clinic further suggest that this type of histological transition may be responsible for resistance to tyrosine kinase inhibitor (TKI) therapy and chemotherapy in relapsed EGFR-mutant lung ADC patients. Here we summarize the current understanding of AST and drug resistance.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  drug resistance; lung adenocarcinoma; lung cancer; squamous transition

Mesh：

Substances：

Year:  2016        PMID： 28741476     DOI： 10.1016/j.trecan.2016.08.002

Source DB:  PubMed          Journal:  Trends Cancer        ISSN： 2405-8025


  11 in total

1.  The Lineage-Defining Transcription Factors SOX2 and NKX2-1 Determine Lung Cancer Cell Fate and Shape the Tumor Immune Microenvironment.

Authors:  Gurkan Mollaoglu; Alex Jones; Sarah J Wait; Anandaroop Mukhopadhyay; Sangmin Jeong; Rahul Arya; Soledad A Camolotto; Timothy L Mosbruger; Chris J Stubben; Christopher J Conley; Arjun Bhutkar; Jeffery M Vahrenkamp; Kristofer C Berrett; Melissa H Cessna; Thomas E Lane; Benjamin L Witt; Mohamed E Salama; Jason Gertz; Kevin B Jones; Eric L Snyder; Trudy G Oliver
Journal:  Immunity       Date:  2018-10-16       Impact factor: 31.745

2.  Integrated analysis of cervical squamous cell carcinoma cohorts from three continents reveals conserved subtypes of prognostic significance.

Authors:  Ankur Chakravarthy; Ian Reddin; Stephen Henderson; Cindy Dong; Nerissa Kirkwood; Maxmilan Jeyakumar; Daniela Rothschild Rodriguez; Natalia Gonzalez Martinez; Jacqueline McDermott; Xiaoping Su; Nagayasau Egawa; Christina S Fjeldbo; Vilde Eide Skingen; Heidi Lyng; Mari Kyllesø Halle; Camilla Krakstad; Afschin Soleiman; Susanne Sprung; Matt Lechner; Peter J I Ellis; Mark Wass; Martin Michaelis; Heidi Fiegl; Helga Salvesen; Gareth J Thomas; John Doorbar; Kerry Chester; Andrew Feber; Tim R Fenton
Journal:  Nat Commun       Date:  2022-10-07       Impact factor: 17.694

Review 3.  Autochthonous murine models for the study of smoker and never-smoker associated lung cancers.

Authors:  Esra A Akbay; James Kim
Journal:  Transl Lung Cancer Res       Date:  2018-08

4.  SNCA Is a Functionally Low-Expressed Gene in Lung Adenocarcinoma.

Authors:  Yuanliang Yan; Zhijie Xu; Xiaofang Hu; Long Qian; Zhi Li; Yangying Zhou; Shuang Dai; Shuangshuang Zeng; Zhicheng Gong
Journal:  Genes (Basel)       Date:  2018-01-04       Impact factor: 4.096

5.  Lkb1 inactivation drives lung cancer lineage switching governed by Polycomb Repressive Complex 2.

Authors:  Haikuo Zhang; Christine Fillmore Brainson; Shohei Koyama; Amanda J Redig; Ting Chen; Shuai Li; Manav Gupta; Carolina Garcia-de-Alba; Margherita Paschini; Grit S Herter-Sprie; Gang Lu; Xin Zhang; Bryan P Marsh; Stephanie J Tuminello; Chunxiao Xu; Zhao Chen; Xiaoen Wang; Esra A Akbay; Mei Zheng; Sangeetha Palakurthi; Lynette M Sholl; Anil K Rustgi; David J Kwiatkowski; J Alan Diehl; Adam J Bass; Norman E Sharpless; Glenn Dranoff; Peter S Hammerman; Hongbin Ji; Nabeel Bardeesy; Dieter Saur; Hideo Watanabe; Carla F Kim; Kwok-Kin Wong
Journal:  Nat Commun       Date:  2017-04-07       Impact factor: 14.919

Review 6.  Pathological transition as the arising mechanism for drug resistance in lung cancer.

Authors:  Yueqing Chen; Waiying Yvonne Tang; Xinyuan Tong; Hongbin Ji
Journal:  Cancer Commun (Lond)       Date:  2019-10-01

7.  c-FOS drives reversible basal to squamous cell carcinoma transition.

Authors:  François Kuonen; Nancy Yanzhe Li; Daniel Haensel; Tiffany Patel; Sadhana Gaddam; Laura Yerly; Kerri Rieger; Sumaira Aasi; Anthony E Oro
Journal:  Cell Rep       Date:  2021-10-05       Impact factor: 9.423

8.  Long non-coding RNA 00960 promoted the aggressiveness of lung adenocarcinoma via the miR-124a/SphK1 axis.

Authors:  Zhipeng Ge; Haibo Liu; Tao Ji; Qiaoling Liu; Lulu Zhang; Pengchong Zhu; Liang Li; Liangming Zhu
Journal:  Bioengineered       Date:  2022-01       Impact factor: 3.269

9.  Acquired Resistance to KRASG12C Inhibition in Cancer.

Authors:  Mark M Awad; Shengwu Liu; Igor I Rybkin; Kathryn C Arbour; Julien Dilly; Viola W Zhu; Melissa L Johnson; Rebecca S Heist; Tejas Patil; Gregory J Riely; Joseph O Jacobson; Xiaoping Yang; Nicole S Persky; David E Root; Kristen E Lowder; Hanrong Feng; Shannon S Zhang; Kevin M Haigis; Yin P Hung; Lynette M Sholl; Brian M Wolpin; Julie Wiese; Jason Christiansen; Jessica Lee; Alexa B Schrock; Lee P Lim; Kavita Garg; Mark Li; Lars D Engstrom; Laura Waters; J David Lawson; Peter Olson; Piro Lito; Sai-Hong I Ou; James G Christensen; Pasi A Jänne; Andrew J Aguirre
Journal:  N Engl J Med       Date:  2021-06-24       Impact factor: 91.245

10.  Dihydroartemisinin sensitizes Lewis lung carcinoma cells to carboplatin therapy via p38 mitogen-activated protein kinase activation.

Authors:  Bicheng Zhang; Zhimin Zhang; Jun Wang; Bo Yang; Yong Zhao; Zhiguo Rao; Jianfei Gao
Journal:  Oncol Lett       Date:  2018-03-15       Impact factor: 2.967
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.